DDO antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q99489 |
Other Accession | NM_003649, NP_003640 |
Reactivity | Human, Rabbit, Pig, Horse, Bovine, Dog |
Predicted | Human, Rabbit, Pig, Chicken, Horse, Bovine, Dog |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 41kDa |
Gene ID | 8528 |
---|---|
Alias Symbol | DASOX, DDO-1, DDO-2, FLJ45203 |
Other Names | D-aspartate oxidase, DASOX, DDO, 1.4.3.1, DDO |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-DDO antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | DDO antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | DDO |
---|---|
Function | Selectively catalyzes the oxidative deamination of acidic amino acids (PubMed:9163533, PubMed:1991137, PubMed:20603179, PubMed:23391306, PubMed:25747990, PubMed:28560262, PubMed:28393897, PubMed:29292239, PubMed:32553892, PubMed:31914658, PubMed:28629864). Suppresses the level of D-aspartate in the brain, an amino acid that can act as an agonist for glutamate receptors (PubMed:28560262). Protects the organism from the toxicity of D-amino acids (By similarity). May also function in the intestine (By similarity). |
Cellular Location | Peroxisome matrix. Cytoplasm, cytosol. Note=Active in the peroxisomal matrix [Isoform 3]: Peroxisome matrix |
Tissue Location | Expressed in epithelial cells of the proximal nephron tubules in the renal cortex (at protein level) (PubMed:1991137, PubMed:12209855). In the brain, expressed in the frontal, temporal, and occipital lobes of the cortex, hippocampus, striatum, diencephalon, brainstem, cerebellum, spinal cord, plexus choroiderus and ependyma (at protein level) (PubMed:12209855, PubMed:28560262). Expression is increased in the prefrontal cortex of schizophrenic patients (PubMed:25689573). Levels are normal in the superior frontal gyrus of patients with Alzheimer's disease (PubMed:30822420) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Setoyama C.,et al.J. Biochem. 121:798-803(1997).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Mungall A.J.,et al.Nature 425:805-811(2003).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Birkett C.,et al.Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.